| Document |
Document Title |
|
WO/2009/118168A1 |
The invention relates to compounds which have an affinity to the µ-opioid receptor and ORL1 receptor, to processes for preparation thereof, to medicaments comprising these compounds and to the use of these compounds for producing medica...
|
|
WO/2009/118538A2 |
The present invention relates to a novel carbohydrate lactone, functionalized aliphatic polyesters and copolymers formed therefrom, and processes for the preparation thereof from renewable resources.
|
|
WO/2009/116657A1 |
A method for producing cycloalkanedicarboxylic acid monoester including, (A) a process for obtaining a compound represented by formula (2) by protecting any one of two compounds of carboxyl groups represented by formula (1) with a group ...
|
|
WO/2009/110003A1 |
The present invention provides a flavonol compound and a bioactive extract/fraction from Ulmus wallichiana useful for the management or prevention or treatment of bone disorders. Said extract/fraction comprising marker compounds of gener...
|
|
WO/2009/108272A1 |
Skin brightening compositions based on esters of 5-hydroxy-2-methyl-4H- pyran-4-one. Also disclosed are methods of making the compositions as well as methods of using the compositions.
|
|
WO/2009/106552A2 |
The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds ...
|
|
WO/2009/104849A1 |
Disclosed are cis-2,6-disubstituted tetrahydropyran derivatives and a preparation method thereof. The tetrahydropyran derivatives can be prepared by Prins-reacting tetrahydropyran derivatives with homopargylicalcohol derivatives in the p...
|
|
WO/2009/096455A1 |
Disclosed is a pharmaceutical composition which is useful as a therapeutic agent for fatty liver diseases. The pharmaceutical composition comprises (1S)-1,5-anhydro-1-[5-(azulen-2-ylmethyl)-2-hydroxyphenyl]-D
-glucitol or a pharmaceutica...
|
|
WO/2009/092702A2 |
The present invention relates to ((2S,4R)-4,6-dihydroxytetrahydro-2H-pyran-2-yl)methyl carboxylates and a process for the production thereof. Furthermore, the present invention relates to a process for the production of statins and in pa...
|
|
WO/2009/089210A1 |
The present invention is directed to novel processes for the preparation of sulfamide derivatves, useful in the treatment of epilepsy and related disorders.
|
|
WO/2009/080761A1 |
A compound of general formula (I) wherein A, Y, W, R1, R2, R3, R4, R5, and R6 take various meanings for use in the treatment of cancer.
|
|
WO/2009/081892A1 |
Disclosed is a compound represented by the general formula (I) below which has a strong COMT inhibitory effect, or a pharmacologically acceptable salt thereof. Also disclosed are a pharmaceutical composition containing such a compound or...
|
|
WO/2009/077186A1 |
The present invention relates to nonsteriodal progesterone receptor modulators of the general formula 1, the use of the progesterone receptor modulators for producing medicaments and also pharmaceutical compositions containing these comp...
|
|
WO/2009/077677A2 |
The invention relates to novel polyspirane compounds used in the treatment of diseases involving parasites that belong to the phylum of apicomplexae, and to a method for preparing the same.
|
|
WO/2009/078033A2 |
The present invention relates to a novel process for isolation and recovery of compounds such as biosynthetically produced simvastatin in either lactone form or in the form of its acid salt in high yield and purity, from microbial fermen...
|
|
WO/2009/077550A1 |
The present invention relates to a method for producing cis-2-(2-methyl-prop-1-ene-yl)-4-methyl-tetrahydropyrane, comprising the catalytic hydration of 2-(2-methyl-prop-1-ene-yl)-4-methylene-tetrahydropyrane in the presence of hydrogen a...
|
|
WO/2009/074314A1 |
Pyrandione, thiopyrandione and cyclohexanetrione compounds, which are suitable for use as herbicides.
|
|
WO/2009/069589A1 |
Disclosed is 1-(2-(4-((2,3-dihydro(1,4)dioxino(2,3-c)pyridin-7-ylmethyl)a
mino)piperidin-1-yl)ethyl)-7-fluoro-1,5-naphthyridin-2(1H)-o
ne monohydrate, which has a strong antibacterial activity. The compound is highly safe and useful as a...
|
|
WO/2009/064418A1 |
The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In...
|
|
WO/2009/059996A1 |
This invention relates to a synthetic nutritional composition suitable for use in the prevention of secondary infections following a viral infection characterised by neuraminidase activitycomprising a sialylated oligosaccharide and N-ace...
|
|
WO/2009/057938A2 |
Provided is a method of preparing a (6R)-3-hexyl-4-hydroxy-6-undecyl-5,6-dihydropyran-2-one, and a (5R)-2-hexyl-5-hydroxy-3-iminohexadecanoate derivative used in said method as an intermediate.
|
|
WO/2009/055516A1 |
The present invention is directed to a process, having a reduced environmental impact, for preparing phenylamino substituted quaternary salt compounds that are CCR2 antagonists.
|
|
WO/2009/055519A1 |
The present invention is directed to a process, having a reduced environmental impact, for preparing phenylamino substituted quaternary salt compounds that are CCR2 antagonists.
|
|
WO/2009/052191A1 |
Internally masked neopentyl sulfonyl ester prodrugs of acamprosate, pharmaceutical compositions comprising such prodrugs, and methods of using such prodrugs and compositions thereof for treating diseases are disclosed. In particular, aca...
|
|
WO/2009/049378A1 |
The present invention relates to bioactive lactone derivatives of formula (I) and pharmaceutical and pesticidal compositions containing them. The present invention also relates to methods of treating bacterial, protozoan, parasitic and f...
|
|
WO/2009/047568A2 |
Certain compounds of Formula (I) or salts thereof are suitable for use in the in vitro preservation of living animal cells. The living animal cells may be isolated cells, such as stem cells, or groups of cells such as tissue or an organ.
|
|
WO/2009/038715A1 |
Disclosed is a process for the preparation of a tetrahydropyran-di-amine represented by Structural Formula (I): wherein R1 is H or alkyl and E is H or an amine protecting group.
|
|
WO/2009/038719A1 |
Disclosed is a process for the preparation of a tetrahydropyran-di-amine represented by Structural Formula (I): wherein R1 is H or alkyl and E is H or an amine protecting group.
|
|
WO/2009/030716A1 |
The present invention relates to 1-(1-methylethyl)-4-{[4-(tetrahydro-2H-pyran-4-yloxy)phenyl]
carbonyl}piperazine (Formula) or a pharmaceutically acceptable salt thereof, in particular the hydrochloride salt thereof and crystalline forms...
|
|
WO/2009/031437A1 |
Disclosed is a liquid crystalline compound which has stability to heat, light and the like, exhibits a nematic phase in a wide temperature range, has a low viscosity, adequate optical anisotropy and an adequate elastic coefficient K33, a...
|
|
WO/2009/028284A1 |
[PROBLEMS] To provide a process for producing an (R)-2-alkylcyclopentanone and an (R)-δ-lactone (which are useful as perfume components or the like) in a simple and inexpensive manner, in high yield and at high optical purity without pu...
|
|
WO/2009/024550A1 |
The present invention relates to N-benzyl,N' -arylcarbonylpiperazine derivatives having the general Formula (I) to pharmaceutical compositions comprising the same, and to the use of a these N-benzyl,N' -arylcarbonylpiperazine derivatives...
|
|
WO/2009/021943A2 |
The present invention relates to a process for preparing compounds of the general formula (I) in which R1 and R2 are defined as mentioned in the description, the pharmaceutically acceptable salts thereof and the solvates thereof, which c...
|
|
WO/2009/019900A1 |
It is intended to provide an industrial purification method for PDC obtained by fermentative production. A purification method for 2-pyrone-4,6-dicarboxylic acid, characterized by allowing a monovalent to tetravalent cationic salt to exi...
|
|
WO/2009/016375A2 |
Polyglycerol ethers of sorbitan carboxylic acid, particularly C8 to C22 carboxylic acid, esters are new surfactant compounds, useful as emulsifiers. Desirable compounds are of the formula (I): Sor(R1)(R2)(R3)(R4) where R1, R2, R3, R4 hav...
|
|
WO/2009/013764A2 |
Disclosed herein is an improved process for producing HMG-CoA reductase inhibitor, 6(R)-[2-(8 '(S)-2 ",2 ''-dimethylbutyryloxy-2'(S),6 '(R)-dimethyl- 1', 2', 6', 7', 8',8a'(R)-hexahydronaphthyl-r(S))ethyl]-4(R)-hydroxy-3,4,5,6
-tetrahydr...
|
|
WO/2009/007015A1 |
The present invention relates to compounds of the formula (I). The compounds of the formula (I) are valuable pharmacologically active compounds. They exhibit a strong anti-thrombotic effect and are suitable, for example, for the therapy ...
|
|
WO/2008/156816A2 |
The present invention is directed to aspartic protease inhibitors. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to ...
|
|
WO/2008/156142A1 |
It is intended to provide a novel compound which has AT2 receptor agonism and is capable of being expected as a pharmaceutical and to provide a therapeutic or preventive method for various diseases. A novel malonic acid sulfonamide deriv...
|
|
WO/2008/155890A1 |
It is intended to provide a method for producing aglycone from a glycoside efficiently at low cost without using an acid catalyst or an organic solvent. The method for producing glycoside aglycone, characterized by bringing a glycoside i...
|
|
WO/2008/156817A2 |
Described are compounds that bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compound...
|
|
WO/2008/156828A2 |
Described are compounds that bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compound...
|
|
WO/2008/142155A2 |
The present invention concerns a method for preparing C-6 phosphorylated D- aldohexoses and C-6 phosphorylated D-aldohexose derivatives, new C-6 phosphorylated D-aldohexoses derivatives and uses thereof. The method comprises incubating p...
|
|
WO/2008/141234A2 |
The invention provides novel compounds that may be used as intermediates in the preparation of epothilones, epothilone analogs and derivative, as well as new synthetic methods for producing the intermediates and products.
|
|
WO/2008/140842A1 |
Compositions and methods for enhancing heavy metal detoxification are described. The compositions and methods described provide enhanced activity of key detoxification systems including that the induction of phase II detoxification enzym...
|
|
WO/2008/130508A1 |
Compounds of Formula I are useful inhibitors of HIF prolyl hydroxylases. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.
|
|
WO/2008/126943A2 |
A method for manufacturing neuraminic acid derivatives is provided, also synthetic intermediates of the neuraminic acid derivatives and methods for their manufacture, and neuraminic acid derivatives having high purity. [Means for solutio...
|
|
WO/2008/125627A1 |
A compound of formula (I) wherein the substituents have various meanings, optionally in salt and/or solvate form, and their use as pharmaceuticals.
|
|
WO/2008/122329A1 |
The present invention provides diol compounds, cosmetic or dermatological sunscreen compositions containing these compounds and the use of these compounds as UV-filters. The compounds are particularly advantageous, because they adhere to...
|
|
WO/2008/119810A2 |
The process for the synthesis of statins featuring the use of an early intermediate (4R,6S)-6-(dialkoxymethyl)tetrahydro-2H-pyran-2,4-diol which already possesses the desired stereochemistry corresponding to the final statin.
|
